Bangkok Genomics Innovation Public (BKGI) Fundamentals 2026 — P/E 17.7x, Revenue Analysis | SniperIQ
Bangkok Genomics Innovation Public (BKGI) is a TH-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ฿1.2B, trading at ฿2.02 on the SET. This SniperIQ fundamentals page covers Bangkok Genomics Innovation Public's valuation (P/E 17.7x, P/B 2.1x), profitability (net margin 15.1%), revenue (฿380M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bangkok Genomics Innovation Public's market cap?
Bangkok Genomics Innovation Public (BKGI) has a market capitalization of approximately ฿1.2B, trading at ฿2.02 on the SET. Market cap moves with the live share price.
What is Bangkok Genomics Innovation Public's P/E ratio?
Bangkok Genomics Innovation Public's trailing twelve-month P/E ratio is 17.7x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bangkok Genomics Innovation Public?
Bangkok Genomics Innovation Public runs a net profit margin of 15.1%, a gross margin of 40.7%, and an operating margin of 16.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bangkok Genomics Innovation Public generate?
Bangkok Genomics Innovation Public reported revenue of ฿380M for fiscal year 2025, with net income of ฿45M and earnings per share (EPS) of 0.0756. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bangkok Genomics Innovation Public pay a dividend?
Bangkok Genomics Innovation Public offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bangkok Genomics Innovation Public financially healthy?
Bangkok Genomics Innovation Public carries a debt-to-equity ratio of 0.03x and a current ratio of 4.58x, with a market beta of 1.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bangkok Genomics Innovation Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bangkok Genomics Innovation Public (BKGI) the key facts are: market cap ฿1.2B, P/E 17.7x, revenue ฿380M, 52-week range 1.2-2.28. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bangkok Genomics Innovation Public's full fundamentals live
Get Bangkok Genomics Innovation Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.